GSK’227 Earns FDA Breakthrough Therapy Designation for Late-Line R/R Osteosarcoma
The FDA has granted breakthrough therapy designation to GSK5764227 for the treatment of relapsed/refractory osteosarcoma.
Related Articles
Multidisciplinary Collaboration Is Crucial in Managing Ocular Toxicities of Mirvetuximab Soravtansine in Gynecologic Tumors
Rebecca Arend, MD, and Kathryn Lyle, CRNP, discuss their approach to managing ocular and other treatment-related toxicities associated with mirvetuximab soravtansine.
Cervical Cancer: Facts, Symptoms, Treatment | OSUCCC – James
Cervical cancer is a rare form of gynecologic cancer. Learn about cervical cancer signs, symptoms, causes and treatments from the OSUCCC – James.
Advancing Cell Therapy Research, Discovery & Innovation : Oncology Times
An abstract is unavailable.
ctDNA Testing Joins NCCN Guidelines for MRD Assessment in DLBCL
The NCCN Guidelines for B-Cell Lymphomas were updated to include ctDNA testing for MRD assessment for patients with PET-positive DLBCL at end of treatment.
Sasanlimab Plus BCG Meets EFS End Point in BCG-Naive, High-Risk NMIBC
Sasanlimab plus BCG improved event-free survival in BCG-naive, high-risk non–muscle-invasive bladder cancer.
Registration | Society of Gynecologic Oncology
The SGO Winter Meeting connects researchers and surgeons at all career stages through scientific sessions, bold discussions, posters, and networking events, while offering winter and…
SPT5 regulates RNA polymerase II stability via Cullin 3–ARMC5 recognition
Phospho-dependent degradation mediated by cullin 3 with ARMC5 adaptor eliminates defective transcription complex lacking SPT5.
Study Reveals a Glass of Milk a Day Could Help Lower Women’s Risk of Colorectal Cancer
A new study found that getting a glass of milk’s worth of calcium per day, whether or not it comes from dairy, can lower colorectal…
Streamlining Regulatory Requirements to Decentralize Cancer … : Oncology Times
An abstract is unavailable.